Immutep Limited (ASX:IMM) Investor Presentation

Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt provides an overview of the company, discussing the LAG-3 immune checkpoint, Immutep’s LAG-3 pipeline, eftilagimod alpha’s potential, and ongoing clinical trials.


Global leaders in the understanding and development of therapeutics that modulate Lymphocyte Activation Gene-3 or “LAG-3” which is a cell surface molecule which plays a vital role in regulating T cells. LAG-3 was discovered by our Chief Scientific Officer and Chief Medical Officer Dr. Frederic Triebel, putting Immutep at the forefront of immunotherapy drugs for cancer and autoimmune diseases.

IMM’s objective is to harness and strengthen the power of the body’s own immune systems through therapeutic intervention for the benefit of patients’ health. This is how immunotherapy fights cancer and autoimmune disease.